Subclinical central inflammation is risk for RIS and CIS conversion to MS

  title={Subclinical central inflammation is risk for RIS and CIS conversion to MS},
  author={Silvia Rossi and Caterina Motta and Valeria Studer and Giulia Macchiarulo and Giorgio Germani and Annamaria Finardi and Roberto Furlan and Gianvito Martino and Diego Centonze},
  journal={Multiple Sclerosis Journal},
  pages={1443 - 1452}
Background: Subtle diffuse intrathecal inflammation is undetectable by conventional neuroimaging, and could influence multiple sclerosis (MS) disease course. Objective: To explore the role of subclinical persisting intrathecal inflammation in radiologically isolated syndrome (RIS) or clinically isolated syndrome (CIS) conversion to MS, and in early MS disease reactivation. Methods: One-hundred ninety-three subjects with RIS, CIS, relapsing–remitting (RR), or primary progressive (PP) MS were… 

Figures and Tables from this paper

Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome
Biological markers that may help refine the risk stratification of clinical MS and disability for early treatment are focused on, as early as possible, for predicting greater disease severity.
[Radiologically isolated syndrome: prognosis and predictors of conversion to multiple sclerosis].
The identification of the molecular biological RIS features, combining these changes with MS, is an urgent scientific task and will allow timely initiation of therapy of the pathological process already at the subclinical stage.
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course
Delayed diagnosis and treatment initiation are associated with higher CSF levels of IL-6 and IL-8 in RR-MS, leading to worsening disease course and poor response to treatments.
IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis
It is found that IL-6 was more frequently detectable in the CSF of MS patients compared with their control counterparts as significant differences emerged between patients with Clinically isolated syndrome, Relapsing–remitting (RR), and secondary progressive and primary progressive MS compared to non-inflammatory controls.
Radiologically isolated syndrome and multiple sclerosis.
Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis
Following the extraordinary progress in the treatment of multiple sclerosis (MS), two major unmet needs remain: understanding the etiology of the disease and, hence, designing definitive cures (this
Drug Treatment of Clinically Isolated Syndrome
The available data on the efficacy, safety and tolerability of DMTs tested for CIS are reviewed and their value regarding a delay of progression to CDMS is discussed.
Radiologically isolated syndrome and clinically isolated syndrome
The present review discusses the current concepts of RIS and CIS, and the risk factors for conversion from these conditions to MS, and that early treatment with these drugs could improve future disease prognosis in patients who subsequently developed MS.
Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients
There is a pressing need to provide an update on the main prognostic factors that increase the risk of conversion from CIS or from radiologically isolated syndrome to MS, and on the potential ‘red flags' to consider during the diagnostic workup.
Update on clinically isolated syndrome.


Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
TheChemokine CXCL13 may play a major role in recruitment of B cells and T-cell subsets expressing the chemokine receptor CXCR5 to the CNS in multiple sclerosis (MS), and may be a useful biomarker for treatment effects in MS.
Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome
It is suggested that the presence of asymptomatic spinal cord lesions place subjects with RIS at substantial risk for clinical conversion to either an acute or progressive event, a risk that is independent of brain lesions on MRI.
Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event
Data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom, and an age <37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.
The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)
The data indicate the relevance of CXCL13 in CIS to predict conversion to MS and shows CxCL13 to be an important mediator in the inflammatory cascade associated with the polyspecific intrathecal B cell response that manifests itself in OCB and MRZR.
Cerebrospinal Fluid IL-12p40, CXCL13 and IL-8 as a Combinatorial Biomarker of Active Intrathecal Inflammation
Future clinical studies will determine if a combinatorial biomarker consisting of CSF IL-12p40, CXCL13 and IL-8 provides utility in determining the presence of active intrathecal inflammation in diagnostically uncertain cases and in therapeutic development and management.
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
Data support an immunopathogenetic mechanism whereby B-cell follicles developing in the multiple sclerosis meninges exacerbate the detrimental effects of humoral immunity with a subsequent major impact on the integrity of the cortical structures.
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration
The results point to TNF as a primary neurotoxic molecule in progressive forms of MS and suggest a pathogenic role of B cells in TNF CSF increase, exacerbation of glutamatergic transmission and neuronal damage.
Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid
This is the first study to show that natalizumab treatment is associated with a global decline in cytokine and chemokine levels at a protein level, and this finding was most pronounced in CSF, in line with the reduced transmigration of cells into CNS, whereas reduction in plasma levels indicates other possible mechanisms of natalizer treatment.
Diagnostic criteria for multiple sclerosis